DC-806 clinical trials
Also written DC-806 and LY4100504.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses DC-806 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 4 |
Who runs them
Industry 5 · Other 0
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (5)
Studies
Open first, then newest update. How each study uses DC-806 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy ParticipantsCompletedPhase 1DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06092931Written as DC-806
- A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult ParticipantsCompletedPhase 1DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT05994807Written as DC-806
- Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male ParticipantsCompletedPhase 1DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06045000Written as DC-806
- A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque PsoriasisCompletedPhase 2DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT05896527Written as DC-806
- A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque PsoriasisCompletedPhase 1DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06808815Written as DC-806
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted2
- A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult ParticipantsOct 19, 2026NCT05994807
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy ParticipantsOct 19, 2026NCT06092931